BAUSCH HEALTH AMERICAS, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
3.1K
Market Cap
-
Website
http://www.bauschhealth.com
Clinical Trials
Related News

Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

First Posted Date
2011-09-01
Last Posted Date
2018-01-18
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
2154
Registration Number
NCT01427296

Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea

Phase 3
Completed
Conditions
HIV Enteropathy
Diarrhea With HIV
Interventions
Drug: Crofelemer
First Posted Date
2011-06-16
Last Posted Date
2020-08-31
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
250
Registration Number
NCT01374490

Compassionate Use Study of Methylnaltrexone

Not Applicable
Completed
Conditions
Opioid-induced Constipation
Interventions
Drug: Methylnaltrexone
First Posted Date
2011-06-08
Last Posted Date
2019-09-04
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
26
Registration Number
NCT01368562
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
6
Registration Number
NCT01367496
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

Phase 1
Completed
Conditions
Healthy Male Volunteers
Interventions
Drug: IV methylnaltrexone (MNTX)
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
6
Registration Number
NCT01367483
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Open-Label Treatment Extension of Protocol MNTX 302

Phase 3
Completed
Conditions
Terminal Illness
Interventions
Drug: SC Methylnaltrexone
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
89
Registration Number
NCT01367613
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus

First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
65
Registration Number
NCT01367548
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
54
Registration Number
NCT01367535
Locations
🇺🇸

Progenics Pharmaceuticals, Tarrytown, New York, United States

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

Phase 1
Completed
Conditions
Renal Impairment
Interventions
Drug: Methylnaltrexone (MNTX)
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
32
Registration Number
NCT01367509
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Open-Label Treatment Extension of Protocol MNTX 301

Phase 3
Completed
Conditions
Terminal Illness
Interventions
Drug: SC Methylnaltrexone (MNTX)
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
27
Registration Number
NCT01367600
Locations
🇺🇸

Progenics Pharmaceuticals, Tarrytown, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy